Drug Trial Radar · NCT07416539
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Rokote Laboratories Finland OyIndustry
- Sponsor type
- Industry
- Collaborators
- Oy Medfiles Ltd; Estimates OY
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein. Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28. This trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.
Conditions
- COVID - 19
- SARS CoV-2
Interventions
COVID-19 VaccinesBiological
COV2 vaccine given in formulation A in 2 doses as a nasal spray, 28 days between each dose.
COVID-19 VaccinesBiological
COV2 vaccine given in formulation B in 2 doses as a nasal spray, 28 days between each dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary safety endpointsTime frame: From Day 0 to day 56
- Primary immunogenicity endpointTime frame: Day 56 from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kuopio University Hospital, ENT policlinic
Kuopio, Northern Savonia, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.